Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD30

CD30

Brief Information

Name:Tumor necrosis factor receptor superfamily member 8
Target Synonym:CD30,CD30L receptor,TNFRSF8,Lymphocyte activation antigen CD30,TNF Receptor Superfamily Member 8,D1S166E,Tumor Necrosis Factor Receptor Superfamily, Member 8,Cytokine Receptor CD30,CD30 Antigen,Ki-1,Ki-1 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 8
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD0-HF2H4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human CD30, His Tag (Cat. No.CD0-HF2H4) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD0-HP2E3-Cell-based assay
 CD30 FACS

5e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD30, His Tag (Cat. No. CD0-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

TN8-H5250-BLI
 CD30 BLI

Loaded Human CD30 Ligand, His Tag (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD0-H82E6-BLI
 CD30 BLI

Loaded Biotinylated Human CD30, Avitag,His Tag (Cat. No. CD0-H82E6) on SA Biosensor, can bind Human CD30 Ligand, His Tag, low endotoxin (Cat. No. CDL-H524b) with an affinity constant of 139 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

TNFRSF8,CD30,D1S166E,Ki-1

Background

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brentuximab vedotin cAC10-vcMMAE; cAC10-Val-Cit-MMAE; SGN-30; SGN-35; cAC-10; SGD-1010 Approved Millennium Pharmaceuticals Inc, Seattle Genetics Inc 安适利, Adcetris United States Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic Seattle Genetics Inc 2011-08-19 Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Sezary Syndrome; Scleroderma, Diffuse; Lymphoma, Non-Hodgkin; Hidradenitis Suppurativa; Lymphoma; Mesothelioma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Mycosis Fungoides; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Lymphomatoid Papulosis; Hematologic Diseases; Leukemia, Mast-Cell; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Mastocytosis, Systemic; Enteropathy-Associated T-Cell Lymphoma; Graft vs Host Disease; Neoplasms; Hodgkin Disease; Carcinoma; Anemia, Refractory, with Excess of Blasts; Lymphoma, B-Cell; HIV Infections; Lymphoma, T-Cell, Peripheral; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Inc Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic Details
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Solid tumours; Leukemia; Chondrosarcoma; Neoplasms; Hodgkin Disease; Neuroblastoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous Details
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 F0002-ADC; B-006 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral Details
Anti-CD30 CAR-T cell therapy (National Cancer Institute) Hu30-CD28z Phase 1 Clinical National Cancer Institute Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma Details
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell Details
CD30.CAR H-27721; CD30.CAR Phase 1 Clinical Baylor College Of Medicine Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Hodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic Details
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta Phase 2 Clinical Pla General Hospital Hodgkin Disease Details
Acimtamig AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides Details
SGN-35T SGN-35T Phase 1 Clinical Seagen Inc Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic Details
EBV-specific-CAR.CD30 EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs Phase 1 Clinical Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System Hodgkin Disease; Lymphoma, Non-Hodgkin Details
GEN3017 GEN-3017 Phase 2 Clinical Genmab A/S Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin Details
PRA-052 PRA-052 Phase 1 Clinical Prometheus Biosciences Inc Colitis, Ulcerative Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) Phase 2 Clinical Unc Lineberger Comprehensive Cancer Center Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Hodgkin Disease; Neoplasms; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms, Germ Cell and Embryonal Details
HSP-CAR-30 HSP-CAR-30 Phase 2 Clinical Fundació Institut De Recerca De L Hodgkin Disease; Lymphoma, T-Cell Details
Anti CD30 CAR T Cell Therapy (First Song Therapeutics) Phase 1 Clinical Zhejiang University Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic Details
CD30.CAR-EBVST cell therapy (Baylor College of Medicine) TT-11X Phase 1 Clinical Baylor College Of Medicine, Tessa Therapeutics Ltd Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell Details
Itezocabtagene autoleucel TT-11; TT11 Phase 2 Clinical Tessa Therapeutics Ltd Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message